# Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

> **NCT04606394** · PHASE4 · COMPLETED · sponsor: **Pulmonary Research Institute of Southeast Michigan** · enrollment: 30 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Trelegy Ellipta 100/62.5/25Mcg Inh 30D
- **DRUG:** Ventolin 90Mcg/Actuation Inhalation Aerosol

## Key facts

- **NCT ID:** NCT04606394
- **Lead sponsor:** Pulmonary Research Institute of Southeast Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-02
- **Primary completion:** 2021-12-15
- **Final completion:** 2021-12-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04606394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04606394, "Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04606394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*